Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain. (PPPCARE II)

University Hospital, Rouen

Status

Enrolling

Conditions

Acute Pathology of the Locomotor System

Treatments

Other: personalized pharmaceutical plan

Study type

Interventional

Funder types

Other

Identifiers

NCT05905146

2020/0426/HP

Details and patient eligibility

About

The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.

Enrollment

200 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient hospitalized in the rheumatology department
Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion

Exclusion criteria

Patient with cancer or fibromyalgia already diagnosed at inclusion
Patient with poor French language skills
Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
Patient already included in the study